论文部分内容阅读
Approximately 400 million people are chronic HBV surface antigen carriers.There is a pressing need to improve therapeutic options for chronic hepatitis B.Pegylated interferon alpha (Peg-IFN-α) achieves sustained off-treatment responses in more cases than other existing treatments because of its direct anti-viruses effect and regulation of immunity.